The approval makes Dupixent the first FDA-approved therapy for allergic fungal rhinosinusitis, supported by Phase III data showing significant improvements in sinus opacification, nasal symptoms, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results